Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inspire Medical Systems (INSP) EBITDA (2017 - 2025)

Inspire Medical Systems (INSP) has disclosed EBITDA for 9 consecutive years, with $135.9 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 299.05% to $135.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $145.4 million through Dec 2025, up 172.98% year-over-year, with the annual reading at $145.4 million for FY2025, 172.98% up from the prior year.
  • EBITDA hit $135.9 million in Q4 2025 for Inspire Medical Systems, up from $10.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $135.9 million in Q4 2025 to a low of -$17.0 million in Q3 2022.
  • Historically, EBITDA has averaged $4.6 million across 5 years, with a median of -$6.0 million in 2023.
  • Biggest five-year swings in EBITDA: soared 352.85% in 2023 and later tumbled 135.83% in 2025.
  • Year by year, EBITDA stood at -$2.4 million in 2021, then surged by 240.62% to $3.4 million in 2022, then surged by 352.85% to $15.5 million in 2023, then skyrocketed by 119.47% to $34.1 million in 2024, then soared by 299.05% to $135.9 million in 2025.
  • Business Quant data shows EBITDA for INSP at $135.9 million in Q4 2025, $10.2 million in Q3 2025, and -$3.4 million in Q2 2025.